Table 1 Patient and melanoma disease characteristics
Characteristic | All AVAST-M trial patients N (%) | Vitamin D cohort N (%) | Bevacizumab N (%) | Observation N (%) | Stage II disease N (%) | Stage III disease N (%) |
|---|---|---|---|---|---|---|
1343 | 341 | 171 | 170 | 90 | 251 | |
Gender | ||||||
Male | 753 (56) | 186 (55) | 88 (51) | 98 (58) | 58 (64) | 128 (51) |
Female | 590 (44) | 155 (45) | 83 (49) | 72 (42) | 32 (36) | 123 (49) |
Age in years, median [range] | 56 (18–88) | 55 (19–86) | 55 (19–80) | 56 (19–86) | 64 (23–86) | 53 (19–80) |
BMI kg/m2, median [range] | 27.6 [15.7–68.6] | 26.8 [15.8–57.6] | 27.1 [15.8–57.6] | 26.5 [19.4–46.2] | 28.4 [19.7–40.1] | 26.4 [15.8–57.6] |
Time from initial melanoma diagnosis to randomisation in years, median [range] | 0.46 [0–29.3] | 0.47 [0–22.6] | 0.45 [0.12–18.3] | 0.48 [0–22.6] | 0.32 [0.13–0.45] | 0.64 [0–22.6] |
<1 | 912 (68) | 233 (68) | 120 (70) | 113 (67) | 90 (100) | 143 (57) |
1–2 | 130 (10) | 40 (12) | 21 (12) | 19 (11) | 0 | 40 (16) |
>2 | 301 (22) | 68 (20) | 30 (18) | 38 (22) | 0 | 68 (28) |
Primary melanoma Breslow thickness at diagnosis, in mm | ||||||
≤2 | 399 (30) | 103 (30) | 51 (30) | 52 (31) | 0 | 103 (30) |
>2–4 | 405 (30) | 107 (31) | 54 (31) | 53 (31) | 24 (27) | 83 (33) |
>4 | 438 (33) | 111 (33) | 56 (33) | 55 (32) | 66 (73) | 45 (18) |
Unknown | 101 (7) | 20 (6) | 10 (6) | 10 (6) | 0 | 20 (6) |
Primary melanoma ulceration at diagnosis | ||||||
Present | 518 (39) | 137 (40) | 70 (41) | 67 (39) | 67 (74) | 70 (28) |
Absent | 633 (47) | 151 (44) | 68 (40) | 83 (49) | 20 (22) | 131 (52) |
Unknown | 192 (14) | 53 (16) | 33 (19) | 20 (12) | 3 (3) | 50 (20) |
Disease stage at trial entry | ||||||
II | 364 (27) | 90 (27) | 48 (28) | 42 (24) | ||
IIIA | 195 (15) | 52 (15) | 27 (16) | 25 (15) | ||
IIIB | 495 (37) | 113 (33) | 54 (32) | 59 (35) | ||
IIIC | 289 (21) | 86 (25) | 42 (24) | 44 (26) | ||
